Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 1, 2020
NEWTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of...
-
May 28, 2020-- Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) --
NEWTON, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today reported detailed results from the pivotal, Phase 3...
-
May 26, 2020-- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET --
NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
May 26, 2020-- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET --
NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
May 20, 2020
NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced it has submitted a supplemental New Drug...
-
May 13, 2020
NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute...
-
May 12, 2020Fireside Chat Scheduled for Tuesday, May 19, 2020, at 8:35 a.m. ET
NEWTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
May 5, 2020-- Pivotal Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival; Oral Presentation at ASCO 2020 Virtual Scientific Program and sNDA To Be Submitted by End of May 2020 --
NEWTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended...
-
May 1, 2020
NEWTON, Mass., May 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of...
-
Apr 29, 2020- A Total of Five Abstracts Selected for Presentation, Including Two Highlighting Data from the Darzalex® and Kyprolis® Arms of the Phase 1b/2 STOMP Study -
NEWTON, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that its late-breaking abstract detailing...